Brukinsa (zanubrutinib) vs Jaypirca (pirtobrutinib)
Brukinsa (zanubrutinib) vs Jaypirca (pirtobrutinib)
Brukinsa (zanubrutinib) and Jaypirca (pirtobrutinib) are both Bruton's tyrosine kinase (BTK) inhibitors used to treat certain types of B-cell malignancies, but they have different profiles. Zanubrutinib is approved for the treatment of mantle cell lymphoma and Waldenström's macroglobulinemia, and is known for its selective inhibition of BTK, potentially offering a favorable safety profile. Pirtobrutinib, on the other hand, is designed to be a non-covalent BTK inhibitor, which may allow it to overcome resistance seen with other BTK inhibitors, and is currently being evaluated for efficacy in patients who have previously been treated with other BTK inhibitors. When deciding which medication is right for an individual, it is crucial to consider the specific type of cancer, prior treatments, the drug's safety profile, and the mechanism of action, as well as to consult with a healthcare provider for a personalized treatment plan.
Difference between Brukinsa and Jaypirca
| Metric | Brukinsa (zanubrutinib) | Jaypirca (pirtobrutinib) |
|---|---|---|
| Generic name | Zanubrutinib | Pirtobrutinib |
| Indications | Mantle cell lymphoma, Waldenström's macroglobulinemia | Relapsed or refractory mantle cell lymphoma |
| Mechanism of action | Bruton's tyrosine kinase (BTK) inhibitor | Bruton's tyrosine kinase (BTK) inhibitor |
| Brand names | Brukinsa | Jaypirca |
| Administrative route | Oral | Oral |
| Side effects | Neutropenia, thrombocytopenia, anemia, diarrhea, cough | Thrombocytopenia, neutropenia, anemia, fatigue, musculoskeletal pain |
| Contraindications | Hypersensitivity to zanubrutinib | Hypersensitivity to pirtobrutinib |
| Drug class | BTK inhibitor | BTK inhibitor |
| Manufacturer | BeiGene | Loxo Oncology at Lilly |
Efficacy
Brukinsa (Zanubrutinib) Efficacy in Treating Lymphoma
Brukinsa (zanubrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor that has been approved for the treatment of mantle cell lymphoma (MCL) in patients who have received at least one prior therapy. Clinical trials have demonstrated the efficacy of zanubrutinib in inducing a high rate of response in patients with relapsed or refractory MCL. The overall response rate (ORR) reported from these studies is significant, with many patients achieving a complete response (CR). Moreover, zanubrutinib has been shown to have a manageable safety profile, which is critical for patients undergoing cancer treatment.
In addition to MCL, zanubrutinib is being investigated for its efficacy in other B-cell malignancies, including different types of lymphoma such as Waldenström's macroglobulinemia (WM) and marginal zone lymphoma (MZL). Early clinical data suggest that zanubrutinib may offer therapeutic benefits in these conditions as well, with ongoing studies aiming to further define its role and efficacy in the treatment of various lymphoma subtypes.
Jaypirca (Pirtobrutinib) Efficacy in Treating Lymphoma
Jaypirca (pirtobrutinib) is a next-generation BTK inhibitor that has been developed to overcome resistance to first-generation BTK inhibitors. It is designed to bind irreversibly to BTK, and it retains activity against BTK with the C481S mutation, which is a common resistance mechanism. Pirtobrutinib is being evaluated in clinical trials for its efficacy in treating various B-cell malignancies, including lymphoma. Preliminary results have shown promise in patients with B-cell malignancies who have failed previous BTK inhibitor therapies, indicating its potential as a salvage therapy for patients with relapsed or refractory disease.
While pirtobrutinib is not yet approved for the treatment of lymphoma, the ongoing clinical trials are crucial in establishing its efficacy and safety profile. These studies are essential for understanding the full potential of pirtobrutinib in treating lymphomas, particularly for those patients who have developed resistance to existing treatments. As research progresses, pirtobrutinib may become an important option for patients with difficult-to-treat B-cell lymphomas.
Regulatory Agency Approvals
Brukinsa
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Jaypirca
-
Food and Drug Administration (FDA), USA
Access Brukinsa or Jaypirca today
If Brukinsa or Jaypirca are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us